Thyroid | Top 14 novel treatment findings

Levothyroxine improves thyroid function in individuals with Down syndrome

The study found that 79.3% of individuals with Down syndrome had normal thyroid function, while 20.7% exhibited thyroid dysfunction. Early detection and treatment of thyroid issues can lead to improved health outcomes and quality of life for individuals with DS.

Study published: 2021-05-17

Immunotherapy targeting TIGIT and CD96 improves outcomes in papillary thyroid cancer patients.

The identification of novel immunotherapeutic targets may improve treatment strategies for PTC, particularly in patients with lymph node metastasis, enhancing the understanding of the disease's molecular mechanisms.

Study published: 2021-04-08

Poly-zinc-liothyronine improves serum T3 levels in hypothyroid adults

PZL demonstrated a 30% lower Cmax and a delayed peak in serum T3 levels, with a prolonged plateau lasting up to 24 hours, indicating improved stability of serum T3 levels in hypothyroid patients.

Study published: 2021-06-15

RNA interference and gene editing reduce transthyretin amyloid in patients with transthyretin amyloidosis.

The study found a significant association between hepatic expression of TTR and various health outcomes, including increased risk of osteoarthritis, carpal tunnel syndrome, and gastrointestinal diseases, suggesting that transcriptomic regulation may influence these conditions.

Study published: 2021-07-18

Neonatal Bacillus Calmette-Guerin vaccination lowers thyroid-stimulating hormone in individuals with Hashimoto's thyroiditis.

The study highlights that BCG vaccination may be associated with lower TSH levels in subclinical hypothyroidism and a lower rate of Mantoux test reactivity in patients with Hashimoto's thyroiditis, suggesting a potential protective effect against the development of autoimmune thyroid disease.

Study published: 2024-02-29

Levothyroxine normalizes thyroid hormone levels in older patients with thyroid conditions

The study provides insights into the trends of thyroid hormone levels in the Canadian population, which can inform patient screening programs and clinical management of thyroid conditions.

Study published: 2022-04-21

Tyrosine kinase inhibitors improve survival in advanced thyroid cancer

The use of TKIs has been associated with improvements in overall survival, progression-free survival (PFS), and objective response rate (ORR) in patients with advanced and metastatic thyroid cancer.

Study published: 2023-05-08

CAR-T cells effectively target thyroid cancer

The anti-TSHR CAR-T therapy demonstrated strong therapeutic efficacy in vivo, effectively eradicating DTC cell lines and xenograft tumors in a TSHR-specific manner.

Study published: 2021-05-18

Telehealth improves thyroid dysfunction management

Increased access to thyroid care, with 12% of participants opting for telehealth consultations, and 59.3% of those receiving treatment consultations reporting a history of thyroid issues.

Study published: 2022-09-29

Motorized device improves thyroid biopsy outcomes

The motorized FNA device significantly reduced the median number of passes required to obtain adequate samples compared to US-FNA. Adequate samples were obtained after the first pass in 58% of cases with the motorized device, compared to only 11% with US-FNA. The device also demonstrated lower rates of nondiagnostic (2.0%) and indeterminate (8.3%) samples compared to traditional methods.

Study published: 2023-09-11

HPV linked to thyroid eye disease

The study provides molecular evidence linking HPV to TED, highlighting the potential role of viral infections in the disease's pathogenesis and suggesting new avenues for understanding and managing TED.

Study published: 2024-04-30

Tripterygium Glycosides improve TAO treatment

The treatment with Tripterygium Glycosides showed a significantly higher overall effectiveness rate compared to control treatments, with improvements in clinical effectiveness rates for eyeball prominence, CAS score, and FT levels, indicating better management of TAO symptoms.

Study published: 2024-06-25

Atezolizumab increases risk of immune-related adverse events in cancer patients.

The safety profile of atezolizumab is generally consistent across different cancer indications, with lower reported rates of irAEs compared to CTLA-4 inhibitors, suggesting a favorable benefit/risk balance for patients.

Study published: 2022-11-18

Radiomics not superior for hypothyroidism prediction

The study found that radiomic models achieved accuracy comparable to or better than traditional NTCP models, allowing for early identification of patients at risk for RIHT, potentially enabling adjustments in treatment planning to protect the thyroid.

Study published: 2021-09-26